Investigation of Effectiveness of Nowarta110 Against Murine Malignant Melanoma in an Implanted Animal Model.

Abstract

Melanoma is a prevalent and severe disease, making the development of new treatments essential. Nowata110 has demonstrated significant therapeutic efficacy in phase II clinical study against plantar warts. It has shown promising anti-cancer effects in both in vitro and in vivo studies using HPV-16 and HPV-18-induced cervical cancer models. This study evaluated the effectiveness of Nowarta110 in murine melanoma-implanted animals. Nowata110 is a novel compound composed of colloidal silver and fig extract. Male and female immunodeficient C(Cg)-Cd 79 atm 1 (cre) and immunocompetent BALB/c mice were used. Murine melanoma cancer cells (B16-F10) were implanted subcutaneously in experimental animals. Once the top cross-sectional area of tumors reached a minimum of 5 mm2 and approximately 4 mm depth, mice were anesthetized and treated with Nowarta110 intravenously or intratumorally. Control mice received no treatment. In non-treated immunodeficient mice, tumor growth progressed over five weeks, whereas Nowarta110-treated mice drastically reduced tumor volume until five weeks after treatment was initiated. Similarly, in untreated BALB/c mice, tumor growth persisted over five weeks. However, Nowarta110-treated mice exhibited a notable reduction in tumor size. Although intravenous administration of Nowarta110 did not result in complete tumor regression in immunodeficient mice, it did lead to reduced tumor growth. In BALB/c immunocompetent mice, intravenous treatment generally stalled tumor progression. Intratumoral and intravenous administration of Nowarta110 effectively treated murine melanoma in immunodeficient and immunocompetent mice. The Nowarta110 antitumoral efficacy was more pronounced in immunocompetent mice treated intravenously than immunodeficient mice. Clinical studies to examine the efficacy of Nowarta110 in human melanoma and skin cancers are warranted.